D.A. Davidson & CO. raised its holdings in Editas Medicine (NASDAQ:EDIT) by 85.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,102 shares of the company’s stock after purchasing an additional 7,417 shares during the period. D.A. Davidson & CO.’s holdings in Editas Medicine were worth $534,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of EDIT. Glenmede Trust Co. NA bought a new stake in Editas Medicine in the 4th quarter valued at about $153,000. Martingale Asset Management L P bought a new stake in Editas Medicine in the 4th quarter valued at about $219,000. Plancorp LLC bought a new stake in Editas Medicine in the 4th quarter valued at about $235,000. Teacher Retirement System of Texas bought a new stake in Editas Medicine in the 4th quarter valued at about $253,000. Finally, Rothschild Investment Corp IL bought a new stake in Editas Medicine in the 4th quarter valued at about $263,000. 62.98% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have issued reports on the stock. BidaskClub raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a report on Friday. CLSA assumed coverage on shares of Editas Medicine in a report on Tuesday, February 13th. They issued an “underperform” rating for the company. Barclays boosted their price objective on shares of Editas Medicine from $28.00 to $46.00 and gave the company an “overweight” rating in a report on Wednesday, March 7th. Morgan Stanley restated an “equal weight” rating and issued a $43.00 target price (up from $28.00) on shares of Editas Medicine in a research report on Wednesday, March 14th. Finally, Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $46.14.

In related news, CFO Andrew A. F. Hack sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $38.06, for a total transaction of $1,522,400.00. Following the completion of the transaction, the chief financial officer now directly owns 6,000 shares in the company, valued at approximately $228,360. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Katrine Bosley sold 8,333 shares of the company’s stock in a transaction that occurred on Tuesday, May 1st. The stock was sold at an average price of $31.95, for a total transaction of $266,239.35. Following the transaction, the insider now owns 1,301,965 shares of the company’s stock, valued at $41,597,781.75. The disclosure for this sale can be found here. Insiders sold a total of 80,133 shares of company stock valued at $3,001,893 over the last 90 days. Corporate insiders own 19.40% of the company’s stock.

Shares of Editas Medicine opened at $37.98 on Friday, MarketBeat reports. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.71 and a current ratio of 11.71. Editas Medicine has a 12 month low of $36.00 and a 12 month high of $37.13.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Thursday, May 3rd. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.15. The company had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $4.04 million. Editas Medicine had a negative net margin of 707.98% and a negative return on equity of 58.73%. The business’s revenue for the quarter was up 473.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.85) EPS. equities analysts predict that Editas Medicine will post -3 EPS for the current year.

Editas Medicine Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.